A Case of Refractory Polyarticular Juvenile Idiopathic Arthritis Post-hematopoietic Stem Cell Transplantation Successfully Treated With Ruxolitinib.
1/5 보강
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may trigger secondary autoimmune diseases, with autoimmune arthritis representing a rare yet challenging complication.
APA
Sonehara Y, Maruyama Y, et al. (2026). A Case of Refractory Polyarticular Juvenile Idiopathic Arthritis Post-hematopoietic Stem Cell Transplantation Successfully Treated With Ruxolitinib.. Cureus, 18(2), e104044. https://doi.org/10.7759/cureus.104044
MLA
Sonehara Y, et al.. "A Case of Refractory Polyarticular Juvenile Idiopathic Arthritis Post-hematopoietic Stem Cell Transplantation Successfully Treated With Ruxolitinib.." Cureus, vol. 18, no. 2, 2026, pp. e104044.
PMID
41883911 ↗
Abstract 한글 요약
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may trigger secondary autoimmune diseases, with autoimmune arthritis representing a rare yet challenging complication. Here, we report a six-year-old male who developed polyarticular juvenile idiopathic arthritis (JIA) three years after allo-HSCT for lymphoma. Despite resistance to multiple biologic disease-modifying anti-rheumatic drugs (bDMARDs), including adalimumab and tocilizumab, treatment with the Janus kinase 1/2 inhibitor ruxolitinib achieved clinical remission sustained for over two years without significant adverse events or lymphoma relapse. Ruxolitinib may represent a viable therapeutic option for refractory secondary JIA post-allo-HSCT, particularly when conventional bDMARDs fail.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years.
- POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.
- Effective management of pembrolizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with upadacitinib.
- Association of Donor and Recipient Duffy and Kidd Genotypes with GVHD in Leukemia Patients Undergoing Bone Marrow Transplantation.
- Rapid response: Context-dependent immunomodulatory effects of JAK inhibition in the management of severe immune-related adverse events.